TP-508
weak data
The Dose Guy’s verdictOct 27, 20262 sources
TP-508 is one of the few healing peptides on this shelf that have actually been tested in patients, and the early read was good: in a small diabetic foot ulcer trial it more than doubled complete healing. The catch is that the one big trial, in wrist fractures, missed its main goal, the program stalled, and the human data covers micrograms dabbed on a wound and a wrist fracture study, not the daily systemic pin people picture. If you have a stubborn wound or a slow fracture and want real receipts, it is a reasonable under-the-radar pick. For the usual gym tendon or joint complaint, BPC-157 and TB-500 are still where to start.
What it is
A 23-amino-acid peptide cut from thrombin, the clotting enzyme, but from the part that talks to cells rather than the part that clots blood. It carries an RGD sequence, a short motif that grips integrins, the anchor proteins cells use to sense injured tissue, and in endothelial cells that grip switches on nitric oxide and new blood-vessel sprouting. More blood supply into damaged tissue is the whole theory of how it heals things.
On the healing shelf it sits off to the side of BPC-157 and TB-500. Those two have the community mileage and almost no human trials; TP-508 has the human trials and almost no community mileage. It was developed as a drug for ulcers and fractures, then later repositioned as a radiation-injury countermeasure, so its evidence points at wounds and bone, not tendons and guts.
What the research shows
A real phase 1/2 trial with a strong signal, a phase 3 that half-landed, and a big animal base behind both. Small, honest, and more than most of this shelf can show:
Realistic protocols
Copy the trials or accept that you are freelancing. The human data covers exactly two shapes. For an open wound, the ulcer trial put 1 or 10 mcg of TP-508 straight onto the cleaned ulcer twice a week, with the higher dose doing better, and it ran on top of proper wound care and offloading, which is what heals most diabetic ulcers in the first place. For a fracture, the wrist study is the only human data, and it hands you no dose to copy at home.
What nobody has tested is the way most people would run it: daily sub-q pins somewhere away from the injury, BPC-style. Gray-market vials push you toward that, and there is no human dose for it. Also mind the scale. A research vial holds hundreds of times the trial dose, so the reconstitution and dilution math is where people go wrong. Nobody has studied what a milligram does.
If your problem is a sore elbow or a tweaked hamstring, TP-508 has no data for it and I would run the BPC-157 and TB-500 stack instead. If it is a diabetic foot wound, the podiatry basics come first; TP-508 is an add-on to them, never a substitute.
Side effects
In the ulcer trial, local reactions and adverse events matched placebo, with no serious drug-related events. That covers topical micrograms, not much else:
